Dec 5 (Reuters) - Teva Pharmaceutical Industries

said on Thursday it will transfer ownership of its

business venture that sold generics in Japan to JKI.

Israel-based Teva's deal with JKI will transfer all the

shares of the unit Teva-Takeda and its subsidiary Teva Takeda

Yakuhin to the firm.

Teva-Takeda is a joint venture established in 2016 by

Japanese drugmaker Takeda and Teva, focusing primarily on the

business of generic and off-patent medicines.

JKI was established by a fund managed and operated by

private equity firm J-Will Partners.

Teva had previously said it was open to exploring new

strategic approaches in Japan, which included the possible

divestment of Teva-Takeda.

The Japanese business venture offers generics and legacy

products.

The world's largest generic drugmaker, Teva, expects the

divestiture to be completed by April 1, 2025.